Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years

Objective To describe the clinical outcome and safety of rituximab (RTX) treatment in systemic lupus erythematosus (SLE) patients with severe manifestations or whose disease is refractory to standard immunosuppressive therapy, treated at a single center. Methods This was a retrospective analysis of...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis care & research (2010) 2017-02, Vol.69 (2), p.257-262
Main Authors: Aguiar, R., Araújo, C., Martins‐Coelho, G., Isenberg, D.
Format: Article
Language:English
Subjects:
Adult
Anti-DNA antibodies
CD19 antigen
Female
Humans
Hypersensitivity
Hypogammaglobulinemia
Immunoglobulin G
Immunoglobulin M
Immunologic Factors - therapeutic use
Immunosuppressive agents
Immunotherapy
Lupus
Lupus Erythematosus, Systemic - drug therapy
Male
Middle Aged
Monoclonal antibodies
Retrospective Studies
Rituximab
Rituximab - therapeutic use
Side effects
Systemic lupus erythematosus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To describe the clinical outcome and safety of rituximab (RTX) treatment in systemic lupus erythematosus (SLE) patients with severe manifestations or whose disease is refractory to standard immunosuppressive therapy, treated at a single center. Methods This was a retrospective analysis of all patients with SLE treated with RTX at 1 center between June 2000 and December 2013. The clinical outcome was assessed by determining British Isles Lupus Assessment Group (BILAG) scores and anti–double‐stranded DNA (anti‐dsDNA) and C3 levels before and 6 months after RTX treatment. For safety analysis, adverse events and deaths were recorded. Results Of a total of 115 patients, 93.9% were female, the mean ± SD age at diagnosis was 26.39 ± 11.90 years, and the mean ± SD disease duration at first RTX treatment was 91.96 ± 84.80 months. A BILAG score variation of −11.26 ± 11.38 (P 
ISSN:2151-464X
2151-4658
DOI:10.1002/acr.22921